Business
QuidelOrtho Completes Debt Refinancing
SAN DIEGO, Aug. 21, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in-vitro
About this update from Quidelortho Corporation
[{"type":"text","content":"SAN DIEGO, Aug. 21, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the \"Company\" or \"QuidelOrtho\"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the completion of a series of related transactions to refinance its debt structure and support future growth. Through these transactions, the Company extended its debt maturities and reduced required amortization payments.\n\n \n \n \n \n \n \n\n \nSummary of New Transactions:\n$1.15 billion 5-year senior secured Term Loan A, which replaces the Company's previous Term Loan A entered into in 2022$100 million delayed draw Term Loan A (undrawn at close)$1.45 billion 7-year senior secured Term Loan B$700 million revolving credit facility, which replaces and pays in full the Company's previous credit facility\"We are pleased to successfully complete our debt refinancing, which allows us to strengthen our capital structure while maintaining financial flexibility,\" said Joseph Busky, Chief Financial Officer, QuidelOrtho. \"Our highest capital allocation priority remains reducing our total debt and net debt leverage. By improving the debt covenant terms and reducing the required amortization over the life of the loan, we will have greater financial flexibility and options to fund the continued growth of our business, while also improving our cash flow.\"\nFor additional information on the terms and conditions, please see the Company's Form 8-K, which was filed with the Securities and Exchange Commission today.\nQuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook and X.\nAbout QuidelOrtho Corporation\nQuidelOrtho Corporation (Nasdaq: QDEL) is a world leader in in vitro diagnostics, developing and manufacturing intelligent in vitro diagnostics solutions that transform data into understanding and action for more people in more places every day. \nBy offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, QuidelOrtho brings fast, accurate and reliable diagnostics when and where they are needed – from home to hospital, lab to clinic.\nBuilding on its long history of innovation, QuidelOrt...